Stockwinners Market Radar for May 10, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:55 EDT Groupon CFO says Q2 revenue to decline at similar rate to Q1 - CFO Jii Ponrt says: "We are providing more details on our expectations for the year. As Dusan mentioned, we expect our second quarter revenues to decline year-over-year at a similar rate to what we observed in the first quarter. And while we expect our third and fourth quarter to decline year-over-year, I would expect to see a slight improvement in the rate of declines each quarter as our transformation strategy takes hold. We expect to see an increase in year-over-year local billings by early 2024, so our revenue growth trends might diverge for our local billing spend depending on the trajectory of our other categories and the timing of our transformation strategy. Turning to profitability, we do expect to generate positive adjusted EBITDA for the remainder of the year as we start to realize the benefits of our restructuring actions more meaningfully. On free cash flow, our ability to convert positive adjusted EBITDA to positive free cash flow will depend on the timing of our working capital cycle and other cash expenses. As a reminder, our working capital has historically been impacted by seasonality, with our first quarter generally experiencing a large negative working capital impact and our fourth quarter experiencing positive working capital. Given our current equity market valuation, our SumUp stake, and our operating plan focus on unlocking both top line growth and expense savings, we believe we can create value for all of our stakeholders as we continue to execute our strategy of transformation." Comments taken from Q1 earnings conference call.

20:07 EDT Cathie Wood's ARK Investment bought 4.4M shares of Palantir today

19:03 EDT Intel, BCG announce collaboration - Boston Consulting Group and Intel "announced a strategic collaboration to enable generative artificial intelligence using end-to-end Intel AI hardware and software, bringing fully custom and proprietary solutions to enterprise clients while keeping private data in the isolation of their trusted environments."

18:32 EDT Apple principal accounting officer Kondo sells 4,092 common shares - In a regulatory filing, Apple principal accounting officer Chris Kondo disclosed the sale of 4,092 common shares of the company on May 8 at a price of $173.26 per share.

18:03 EDT Nutrien cuts FY23 adjusted EBITDA to $6.5B-$8.0B from $8.4B-$10.0B - The company states: "Retail adjusted EBITDA guidance was lowered primarily due to the expectation of below normal crop nutrient gross margins in the first half of 2023 as we work through higher cost inventory. Potash adjusted EBITDA guidance decreased due to lower forecasted benchmark fertilizer prices and sales tonnes. Potash sales tonnes guidance of 13.5 to 14.3 million tonnes assumes increased demand year-over-year in our key markets of North America and Brazil, partially offset by lower shipments to China due to delayed contract negotiations with Canpotex. Nitrogen adjusted EBITDA guidance decreased due to lower forecasted benchmark fertilizer prices, partially offset by the expectation for lower North American natural gas prices."

17:45 EDT Osisko Gold raises quarterly dividend 9.1% to C$0.06 per common share - Osisko Gold Royalties is pleased to announce a second quarter 2023 dividend of C$0.06 per common share, a 9.1% increase over the first quarter of 2023, for an annualized dividend of C$0.24 per share. The dividend will be paid on July 14 to shareholders of record as of the close of business on June 30.

17:37 EDT Cheesecake Factory expects bulk of FY23 new openings in Q4

17:18 EDT Beyond Meat planning major retail marketing push - Says focused on restoring growth in retail grocery. Says planning major retail marketing push. Says will continue to explore time-limited pricing programs. Says targeting cash flow positive operations in 2H23. Comments taken from Q1 earnings conference call.

16:59 EDT Disney says expects $1.5B-$1.8B impairment charge in Q3 from removing content - Says on track to achieve target of $5.5B. Says optimistic on DTC business long term. Says will soon begin offering one app DTC experience domestically. Says will have one-app offering by end of the year. Says experiencing near term macro headwinds. Says pricing changes have proven successful. Says will have higher price for ad-free plans. Says Avengers campus has been a resounding success. Says overall entertainment advertising space has been challenging. Says Disney+ core subscribers grew. Says ESPN+ and Hulu subscribers grew, Sees FY23 cash content spend roughly comparable to last year, excluding writers strike impact. Lowers FY23 capital expenditures view to $5.6B from $6B. Comments and guidance taken from Q2 earnings conference call.

16:51 EDT Groupon sees increase in y/y local billings by early 2024 - The company said, "As our transformation strategy takes hold, we expect to see an increase in year-over-year Local billings by early 2024, though our revenue growth trends may diverge from our Local billings trends depending on the trajectory of our other categories and the timing of our transformation strategy."

16:42 EDT Urban-Gro reports total backlog approximately $105M in contracts - Consolidated backlog is unrealized revenue represented by signed construction design-build, equipment systems, and service orders. As of March 31, total backlog was approximately $105M in contracts, comprised of $96M in construction design-build, $4M of professional services, and $5 million of equipment systems.

16:39 EDT User reports indicate Roblox having issues, says Downdetector - Reference Link

16:35 EDT AppLovin jumps 12% to $19.96 after Q1 results, above-consensus guidance

16:32 EDT Coeur Mining sees FY23 production 100K-112.5K gold oz - FY23 capital expenditures are expected to be $50M - $62M.

16:31 EDT Granite selected by Nevada DOT for $58M Sparks reconstruction contract - Granite has been selected by the Nevada Department of Transportation to reconstruct a section of highway in Sparks, Nevada. The project, valued at approximately $58M, is an extension of the company's award-winning Pyramid and McCarran Intersection Improvement Project, completed in 2017. Funding will come from the Federal Highway Administration and was included in Granite's first-quarter CAP. The Pyramid Highway expansion will convert the four-lane highway into a six-lane high-access arterial road, spanning from Queen Way to Los Altos Parkway. The reconstruction project will include three travel lanes in each direction, bike lanes, curb and gutter enhancements, a wide median, shoulder improvements, and a barrier-protected shared-use path on the east side of the road. Additionally, the stretch between Los Altos Parkway and Golden View Drive will have four travel lanes and improvements, such as sound/screen walls and a protected sidewalk on the west side of the road.

16:21 EDT Digimarc signs multi-year $30M-plus contract - Digimarc "announced a major new contract to protect the authenticity of precious metals and building materials and guard the integrity of a national deposit-return system for recycling. The 5-year contract with an international solutions provider is worth more than $32 million, with the potential to grow significantly based on other optional programs in 2024 and beyond. Under the deal, the Digimarc Illuminate platform will protect the authenticity of gold, silver, platinum, and other precious metals as well as key building materials used in commercial construction. The contract also marks Digimarc's entry into a new market adjacency by guarding the integrity of a national deposit-return system (DRS), combining Digimarc's excellence and expertise in both anti-counterfeiting and recycling to support increased circularity of food and beverage containers."

16:20 EDT PennantPark boosts dividend 8.1% to 20c per share - On May 9 the Company declared a distribution of 20c per share, an increase of 8.1% from the most recent distribution. The distribution is payable on July 3 to stockholders of record as of June 15 and is expected to be paid from taxable net investment income. The final tax characteristics of the distribution will be reported to stockholders on Form 1099 after the end of the calendar year and in the Company's periodic report filed with the Securities and Exchange Commission. "We are pleased to announce another increase in our quarterly dividend, which is well covered by our net investment income," said Arthur Penn, Chairman and CEO. "We are positioned to capture this excellent vintage of investments, which we believe will continue to enhance our earnings over time."

16:19 EDT Independence Realty Trust raises quarterly dividend 14% to 16c per share - Independence Realty Trust announced that IRT's board of directors approved a quarterly dividend of $0.16 per share of IRT common stock, which represents a 14% increase in the dividend over the prior quarterly rate of $0.14 per share. The second quarter dividend is payable on July 21, 2023 to stockholders of record at the close of business on June 30, 2023.

16:19 EDT 4D Molecular expects cash to fund operations into first half of 2026 - The company said, "Cash and cash equivalents and marketable securities were $202 million as of March 31, 2023, as compared to $218 million as of December 31, 2022. The decrease in cash was primarily a result of cash used in operations, which was partially offset by $9.6M of net proceeds from the sale of shares pursuant to our Open Market Sales Agreement. In addition, in May 2023 we completed a public offering of common stock that resulted in us receiving net proceeds of approximately $129 million. We currently expect cash and cash equivalents, inclusive of net proceeds from the May 2023 offering, to be sufficient to fund operations into the first half of half of 2026."

16:12 EDT PLBY Group explores strategic alternatives for Lovers, Honey Birdette - The company said, "The Company's Board of Directors (the "Board") is exploring strategic alternatives for Lovers and Honey Birdette. As part of this process, the Board is considering a full range of strategic alternatives. The Company has retained the Sage Group to assist with the Lovers process and Moelis & Company to assist with the Honey Birdette process. The Company has not set a timetable for completion of this strategic review process, nor has it made any decisions related to its strategic alternatives at this time and does not intend to comment further on the status of this process. There can be no assurance that this strategic review will result in the Company pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms, or at all."

16:10 EDT Disney down 3% in after-hours following Q2 report - Disney shares are down $3.14, or 3% to $98.00 in after-hours trading ahead of the company's earnings call.

16:09 EDT Disney reports Q2 Media and Entertainment Distribution revenue $14.4B, up 3% - Reports Q2 Disney Parks, Experiences and Products revenue $7.78BB, up 17% from last year.

16:08 EDT Disney reports 157.8M Disney+ paid subscribers as of end Q2 - Reports Disney+ paid subscribers of 157.8M as of April 1, down 2% from 161.8M as of December 31, 2022. Reports ESPN+ subscribers of 25.3M, up 2% from 24.9M as of December 31, 2022. Reports total Hulu subscribers of 48.2M, flat with 48.0M as of December 31, 2022.

16:02 EDT Nordstrom names Cathy Smith as CFO, effective May 29 - Nordstrom announced the appointment of Cathy Smith as CFO, effective May 29. Smith joins Nordstrom from Bright Health Group where she has served as chief financial and administrative officer since 2020.

15:06 EDT Altria announces pact to resolve at least 6,000 JUUL-related cases for $235M - Altria Group announces that it has reached agreement on terms to resolve at least 6,000 JUUL-related state and federal cases for $235M. This settlement does not apply to three cases brought by attorneys general, 35 cases brought by Native American tribes, 17 antitrust cases or three Canadian cases, the company noted. The settlement remains subject to the parties entering into one or more final settlement agreements approved by the relevant courts. "We expect to record a pre-tax charge of $235M in the second quarter of 2023 and intend to treat such amount as a special item and exclude it from our adjusted diluted earnings per share," Altria stated. "While we continue to believe the claims against us are meritless, we believe this settlement avoids the uncertainty and expense of a protracted legal process and is in the best interest of our shareholders. This settlement brings to a close the vast majority of our pending JUUL-related litigation," added Murray Garnick, Altria's Executive Vice President and General Counsel.

14:57 EDT Google Pixel Tablet available June 20 starting at $499 - Google introduced the Pixel Tablet, built with the latest Android features, Google Tensor G2 chip and iconic Pixel design. "Pixel Tablet makes it easy to get more done - from working on the go to keeping in touch with family and friends," the company said. "Over 50 Google apps are optimized for the Pixel Tablet, including Google Meet. Google Meet quickly adjusts the lighting as you move around and brings HD video calling to the tablet, so you look your best no matter what you're doing. You can even add a little fun to your video calls with 360-degree backgrounds, like beaches and futuristic cities, that will adjust with you as you move and change positions. Your video chats are always optimized for where you are and how you're lit, moment by moment, thanks to our latest AI camera technology and Tensor G2. That's not all, the tablet's larger screen and AI-powered capabilities help you do even more. Pixel Tablet is the best Pixel device to edit your photos with tools like Magic Eraser and Photo Unblur. With the split screen function, you can use two apps on the screen at the same time. While you're dropping a picture from Google Photos into Gmail, you can also use Assistant voice typing on Pixel Tablet (which is almost three times faster than regular typing) to make writing emails a breeze." The Pixel Tablet comes bundled with the Charging Speaker Dock for $499. Customers can preorder it online starting today in the U.S., Canada, U.K., Germany, France, Sweden, Denmark, Norway, the Netherlands, Japan and Australia at the Google Store and other retailers. It will be available on shelves on June 20.

14:50 EDT Google unveils Pixel 7a, starting at $499 - Google unveiled the Pixel 7a, its latest A-Series phone that "delivers all the helpfulness of Google for less." It's built with flagship processor Google Tensor G2 and dedicated security chip Titan M2. "Pixel 7a is packed with many of the must-have features of our premium phones that are now available on an A-series phone for the first time - like Face Unlock, 8GB of RAM, an up to 90Hz Smooth Display and wireless charging. Pixel 7a provides the core Pixel experience, starting at $499," the company said. "Pixel 7a has the same familiar design as Pixel 7 and 7 Pro, with its iconic Pixel camera bar and smooth, sculpted surfaces. Featuring an all-new midframe architecture, Pixel 7a is our most durable A-series yet. And to support our continued commitment to sustainability, the aluminum housing is made with 100% recycled content." Reference Link

14:45 EDT Google showcases Pixel tablet with home dock, 11-inch display - Says new tablet comes with four speakers, aluminum enclosure, and three microphones.

14:42 EDT Google unveils Pixel 7A phone, available today starting at $499 - Says 7A comes with a 72% bigger main camera sensor thatn 6A. Says new phone available today starting at $499.

14:33 EDT Red Cat reports order for 200 drones for Ukrainian deployment - Red Cat Holdings announces that it will fulfill a purchase order to provide 200 long-range, high-speed FPV drones to Ukrainian drone pilots engaged in conflict with Russia. "Fortunately, Red Cat has the U.S. manufacturing capacity required to quickly deliver on such orders. We are pleased to provide our product to Ukrainian drone pilots, and we look forward to continuing to engage with them, including by providing our new nighttime drone, the Teal 2. Much of drone activity is performed at night, and the Teal 2 is at the forefront of nighttime drone capabilities," said Red Cat CEO Jeff Thompson.

14:24 EDT Google says WhatsApp bringing first ever watch app to Wear OS this summer

14:17 EDT Google says misinformation 'top of mind' in generative AI development - Says working on Universal Translator feature using generative AI. Says seeing "promising results" with Universal Translator. Says Universal Translator built with "guardrails" so that it can only be used by approved partners. Says soon will be integrating new innovations in watermarking into AI-generated content.

14:10 EDT Alphabet Class A shares up 3% as Google's I/O keynote continues - Class A shares of Alphabet (GOOGL) are up $3.58, or 3%, to $110.93 in afternoon trading as the keynote address for Google's annual I/O Conference continues.

14:03 EDT FiscalNote says welected as launch partner for integration with Bard by Google - FiscalNote (NOTE) announced that it has been selected by Google (GOOGL) to be a launch partner for Bard by Google, enabling access to select FiscalNote real-time data sets and content for users. "The announcement was made earlier today at Google's annual I/O Conference in a keynote address by Sissie Hsiao, Vice President and General Manager, Google Assistant and Bard. During the keynote, Google unveiled plans to develop Bard extensions in the coming months, including its ability to integrate with other services across the web, such as FiscalNote's specific datasets. As part of today's Bard announcement, FiscalNote is joining a select group of global brands that are leaders in their respective industry verticals," FiscalNote stated in a press release time with Google's ongoing event.

14:00 EDT SelectQuote named Preferred Medicare Sales and Distribution Partner at Wellcare - SelectQuote (SLQT) announced that Wellcare, the Medicare brand of Centene (CNC), named SelectQuote a Preferred Medicare Sales and Distribution Partner. SelectQuote CEO Tim Danker commented, "We are excited to continue the strong partnership we have built with Wellcare over the past few years. Our differentiated approach in Medicare Advantage, enabled by our agents and technology, is critical to the high-quality sales and customer service we provide American seniors. We are proud to be named a preferred partner and see this designation from Wellcare as further validation that our beneficiary-focused approach produces higher quality volume with strong customer retention."

13:57 EDT Google unveils steps toward improving Search through Generative AI - Google said it is "supercharging search" and offered a look at its first steps toward improving Search with generative AI. "With new generative AI capabilities in Search, we're now taking more of the work out of searching, so you'll be able to understand a topic faster, uncover new viewpoints and insights, and get things done more easily," the company said. "With generative AI in Search, we can help you understand the full picture when you're shopping, making even the most considered and complex purchase decisions faster and much easier. When searching for a product, you'll get a snapshot of noteworthy factors to consider and products that fit the bill. You'll also get product descriptions that include relevant, up-to-date reviews, ratings, prices and product images. That's because this new generative AI shopping experience is built on Google's Shopping Graph, which has more than 35 billion product listings - making it the world's most comprehensive dataset of constantly-changing products, sellers, brands, reviews and inventory out there. In fact, every hour, more than 1.8 billion listings are refreshed in our Shopping Graph to give people fresh, reliable results." "There are known limitations with generative AI and LLMs, and Search, even today, will not always get it right," the company added. "We're taking a responsible and deliberate approach to bringing new generative AI capabilities to Search. We've trained these models to uphold Search's high bar for quality, and we will continue to make improvements over time. They rely on our hallmark systems that we've fine-tuned for decades, and we've also applied additional guardrails, like limiting the types of queries where these capabilities will appear." Reference Link

13:48 EDT Honeywell debuts UOPeFining technology for new class of sustainable jet fuel - Honeywell announced its innovative, new, UOP eFining technology, a ready-now solution for producing low-carbon sustainable aviation fuel, SAF . HIF Global, the world's leading eFuels company, intends to deploy the new technology to produce eSAF at its second U.S. eFuels facility. eFuels, also known as electrofuels, are a class of synthetic fuels that can replace conventionally produced fossil fuels. eFuels combine green hydrogen and carbon dioxide or CO2 to produce eMethanol, which can then be converted to a wide range of sustainable fuels, including eSAF, eGasoline, and eDiesel. Honeywell's UOP eFining is a methanol to jet fuel, MTJ, processing technology that can convert eMethanol to eSAF reliably and at scale. The technology is efficient, resulting in high-yield eSAF production at a lower cost relative to comparable technologies. Honeywell UOP eFining can reduce greenhouse gas emissions by 88% compared to conventional jet fuel1. When blended with conventional jet fuel, eSAF is a drop-in replacement fuel that requires no changes to aircraft technology or fuel infrastructure. "As a leader in renewable fuel technology, Honeywell recognizes that creating technologies that use new feedstocks is vital to long-term decarbonization of the aviation sector," said Lucian Boldea, president and CEO of Honeywell Performance Materials and Technologies. "The ability to use readily abundant CO2 to produce SAF is a transformational opportunity for this market. Adding UOP eFining to our existing Ecofining and ethanol to jet technologies, Honeywell now offers multiple routes to market to meet the rapidly growing demand for renewable fuels including SAF."

13:42 EDT Perrigo announces FDA Advisory Committee votes in favor of Opill for OTC use - Perrigo announced that the U.S. Food and Drug Administration's Nonprescription Drugs Advisory Committee, or NDAC, and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee, or ORUDAC, voted unanimously 17 to 0, with no abstentions, that the benefits of making Opill, a progestin-only daily oral contraceptive, available for over-the-counter use outweighs the risks. "The joint committee's vote, while not binding, will be considered by the FDA when making its final decision regarding the potential approval of Opill for OTC use, which is expected later this year," Perrigo stated.

13:38 EDT Google introduces new updates to Bard AI - Google announced new ways for users to collaborate with Bard. The company said that Bard is now available in Japanese and Korean, and is on track to support 40 languages soon. "Coming soon, Bard will become more visual both in its responses and your prompts," Google added. "You'll be able to ask it things like, "What are some must-see sights in New Orleans?" - and in addition to text, you'll get a helpful response along with rich visuals to give you a much better sense of what you're exploring. You'll also be able to include images - alongside text - in your own prompts, allowing you to boost your imagination and creativity in completely new ways. To make this happen, we're bringing the power of Google Lens right into Bard. Let's say you want to have some fun using a photo of your dogs. You can upload it and prompt Bard to "write a funny caption about these two." Using Google Lens, Bard will analyze the photo, detect the dogs' breeds, and draft a few creative captions - all within seconds." In addition, next week Google will make source citations even more precise, and will in the future introduce new ways for Bard AI to improve experiences on other Google services. "There's a lot ahead for Bard - connecting tools from Google and amazing services across the web, to help you do and create anything you can imagine, through a fluid collaboration with our most capable large language models," the company said. "When we combine human imagination with Bard's generative AI capabilities, the possibilities are boundless. We can't wait to see what you create with it." Reference Link

13:35 EDT Google says new AI features to be available as part of Duet AI for Workspace - Says trusted testers next month will start testing new AI features on Google Workspace. Says new features will be available in the future as part of Duet AI for Workspace.

13:31 EDT Ohmyhome Ltd trading halted, volatility trading pause

13:28 EDT Google says Bard integration with Adobe Firefly in the works - Says Google Bard (GOOG) to become more visual in the next few weeks. Says Bard integration with Adobe Firefly (ADBE) in development. Says company "excited" about partnership with Adobe. Says opening up Bard to over 180 countries and territories today. Says beyond English, you can talk to Bard starting today in Japanese and Korean.

13:25 EDT Crescent Point Energy closes Montney acquisition - Crescent Point Energy announced that it has successfully closed its previously announced strategic and accretive acquisition of oil and liquids-rich Montney assets in Alberta for $1.7B in cash. The company said, "This Acquisition aligns with Crescent Point's long-term strategy and enhances the Company's portfolio by adding 600 high-return Montney locations, further extending its premium drilling inventory to 15 years. This Transaction was also immediately accretive to Crescent Point's adjusted funds flow and excess cash flow per share by 20 percent, resulting in a higher return of capital profile for shareholders. Crescent Point believes these Montney assets have significant upside through a combination of potential reserves growth due to the number of unbooked locations, the opportunity to develop an additional Montney bench based on the significant resource in place and the potential for enhanced efficiencies given the similarities and proximity to its existing Kaybob Duvernay play."

13:22 EDT Google says Bard AI now knows 20 programming languages - Says coding becoming one of the most popular things people are doing in Bard. Says Bard now knows 20 programming languages, including Sheets functions. Says building AI watermarking to curb misinformation. Says tools coming to Bard AI.

13:14 EDT Google announces Magic Editor for Google Photos - Google announced Magic Editor, a new experimental editing experience that uses generative AI to help users reimagine photos and make editing even easier. "With Magic Editor, you'll be able to make complex edits without pro-level editing skills," the company said. "Using a combination of AI techniques, including generative AI, it will help you make edits to specific parts of an image - like the subject, sky or background - so you have even more control over the final look and feel of your photo. Sometimes the difference between a so-so picture and the perfect shot comes down to getting the framing just right. Magic Editor will help you improve the overall composition of your photo by allowing you to reposition the subject of your shot to the best spot." "We plan to give select Pixel phones early access to Magic Editor later this year," the company added. "While this new, experimental technology will open up exciting editing possibilities, we know there might be times when the result isn't exactly what you imagined. Your feedback will be important in helping us improve it over time so you can get the best edits possible." Reference Link

13:11 EDT Google announces Immersive View for routes in Google Maps - In a blog post, Google announced Immersive View for routes in Google Maps, which lets users visualize every segment of a route. "Immersive View uses computer vision and AI to fuse billions of Street View and aerial images together to create a rich, digital model of the world," Google said. "With this technology, you can see all the information you need about your route at once. When you get directions, you'll see a multidimensional experience that lets you preview bike lanes, sidewalks, intersections and parking along your journey. With the time slider, you'll see air quality information and how the route looks as the weather changes throughout the day, so you can be prepared with a jacket or sunscreen. And no matter what mode you take, AI and historical driving trends simulate how many cars might be on the road at a given time - because a route during a quiet afternoon can look very different during rush hour. We'll begin rolling out Immersive View for routes in the coming months in Amsterdam, Berlin, Dublin, Florence, Las Vegas, London, Los Angeles, New York, Miami, Paris, Seattle, San Francisco, San Jose, Tokyo, and Venice." Reference Link

13:08 EDT Google unveils new AI tools Help Me Write for Gmail, Immersive View for Maps - Says has opportunity to make AI "even more helpful" for everyone. Says taking "next step" in AI email capabilities with Gmail Help Me Write, which helps users automatically write a draft email based on limited information. Says Google Maps to get new feature called Immersive View for Routes, which gives users the opportunity to zoom down a 3D representation of their desired route. Says Immersive View will launch in 15 cities by the end of the year. Comments taken from Google I/O keynote presentation.

12:50 EDT Locafy Ltd trading resumes

12:26 EDT AXA Equitable trading resumes

12:03 EDT Equitable sees 50% increase in cash generation over next five years

12:01 EDT Rayonier Advanced Materials falls -18.8% - Rayonier Advanced Materials is down -18.8%, or -$1.03 to $4.45.

12:00 EDT MasterBrand rises 18.4% - MasterBrand is up 18.4%, or $1.59 to $10.23.

12:00 EDT Compass rises 32.5% - Compass is up 32.5%, or 91c to $3.71.

11:46 EDT Etsy launches wedding registry feature Etsy Registry - In a blog post, Etsy trend expert Dayna Isom Johnson said, "As the wedding gift-giving industry evolves and more people shop with intention, Etsy is thrilled to announce Etsy Registry, our new wedding registry experience that allows couples to register for truly meaningful gifts - often personalized or one-of-a-kind. On Etsy, we've seen a staggering 872% increase in searches on Etsy for handmade gifts telling us that couples and their guests are moving away from mass-produced gifts. Starting today, couples can visit Etsy.com/Registry to easily create, manage, and share their registries. In addition to handmade and vintage, couples can also register for personalized items and specify the exact customization for their guests, making Etsy a one-stop-shop for gifts, wedding decor, and even bridal party items - all while supporting small businesses." Reference Link

11:09 EDT Air Products announces $10M investment to increase membrane production capacity - Air Products announced a project to significantly increase hollow fiber membrane production at its St. Louis, Missouri facility. The production improvement project at the facility is driven by strong customer demand in the biogas and hydrogen recovery applications, as well as customer needs for the use of nitrogen for the aerospace industry and dehydration products. This capacity improvement effort will impact product lines such as the PRISM(R) GreenDry membrane dryer and the PRISM GreenSep membrane separator, which provide customers in the biogas industry with dehydration and upgrading solutions that add design flexibility to a customer's biogas system. The project also increases the production of PRISM N2Sep membranes, which are the foundation of Air Products' recently announced PRISM InertPro Membrane System, a new nitrogen generator for the energy and gas industry that is optimized with a flexible modular design to focus on efficiency and lower energy nitrogen generation.

10:51 EDT Reata says FDA approval of application supplement needed for Skyclarys - In Q1, the FDA approved of Skyclarys for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older. Reata Pharmaceuticals disclosed in today's earnings release that it has received approximately 500 patient start forms to date. The company said it has completed the final stages of Skyclarys drug product manufacturing and packaging. A new drug application supplement was submitted to the FDA to increase the drug substance specification for a process impurity that was observed above the current specification during process validation. The approval of this supplement is required to release Skyclarys drug product to the company's specialty pharmacy. The FDA is reviewing the supplement as a Prior Approval Supplement under Priority Review with an approval target action date in mid-August, Reta said. The FDA stated that the review of the supplement was prioritized and that the approval potentially should come earlier than the action date, it added. The company believes the information provided in the NDA supplement is sufficient to support the proposed change. Provided that there are no major review issues with the supplement, Reata believes Skyclarys will be available through the specialty pharmacy no later than mid-August.

10:24 EDT Unique Fabricating says 'no news' to account for increase in trading activity - The company said, "The Company has no news to announce at this time that would account for the increase in trading activity of its shares of common stock."

10:09 EDT ATI Physical Therapy opens two additional Dallas locations - ATI Physical Therapy announced the opening of two new locations in the growing Dallas-Fort Worth metroplex, bringing its total number of clinics in the market to 55. The expansion creates even more opportunity for Dallas-area residents to access high quality care, personalized service and treatment by dedicated therapists chosen from some of the best clinicians in the industry.

10:08 EDT Cinedigm says RetroCrush DTC app sees monthy active users up 660% - The company said, "RetroCrush, experiencing strong distribution and subscriber growth, is turning anime into a red-hot genre among the Cinedigm (NASDAQ: CIDM) family of channels. The surge of the genre gives Cinedigm, the premier independent streaming entertainment company super-serving enthusiast audiences, another expanding content category - alongside other genres such as horror and faith & family...Thanks to new distribution and continued growth across paid subscribers, YouTube and its social footprint, and overall monthly viewership across its SVOD, AVOD and FAST offerings, RetroCrush has become the top independent anime streaming brand. During the last year, the RetroCrush FAST channel has added distribution partnerships that include Samsung TV Plus, Sling TV, Philo and Amazon Freevee. Additionally, Cinedigm has announced today the rebranding of its Viewster Anime channel as RetroCrush - now available as an a la carte SVOD option on The Roku Channel. Concurrently, RetroCrush has begun to roll out its newest version, powered by Cinedigm's proprietary Matchpoint Blueprint 2.0 platform, across desktop, mobile and CTV devices. During the last year, since Cinedigm acquired RetroCrush from DMR RetroCrush's DTC app has seen its monthly active users rise 660 percent, minutes watched jump 95 percent, and paid subscribers rise 17 percent year-over-year. On social media, RetroCrush's YouTube subscriber base jumped 15 percent to nearly 900,000 subs, making it Cinedigm's second most subscribed YouTube channel after only AsianCrush, and its total Instagram followers rose 4X during the same period of time."

10:04 EDT Nymox expects submission for marketing approval of Nymozarfex in Q2 - Nymox Pharmaceutical Corporation provides a mid-2nd quarter update on ongoing activities. The Company reported last month that it expects to submit an additional new submission for marketing approval of Nymozarfex, the Company's first in class molecular treatment for benign prostate enlargement. The Company expects to report further details once the application is submitted, which is expected this quarter as earlier announced. Nymozarfex is the first of its kind, as a painless long lasting BPH focally delivered molecular treatment with no long lasting adverse effects. Nymozarfex is given once in a convenient office administration lasting a few minutes, without catheter and without anesthesia. Nymox is also pleased to report that it has gained a large number of new patent approvals in the past 12 months in jurisdictions around the world further reinforcing the Company's intellectual property protections for the technologies owned and developed by the Company. Prostate enlargement occurs as men get older and it is near the top of every list among the most prevalent conditions in the adult male population. BPH leads to a variety of bothersome urination problems and these can often become very serious if not brought under control. For many men unfortunately the outcome becomes that surgery is needed. BPH affects all adult male populations throughout the world and does not spare any race or region. As men get into their 70's and older, the prevalence in the male population of some degree of BPH is estimated to be in the 80 to 90% range. Frequent urination interrupts sleep and disrupts most normal activities. Dribbling and incontinence can occur. Inability to urinate can result in medical emergencies with catheterization in hospital. Total obstruction can cause renal damage and other serious complications. Most men who start oral medications stop the medications due to the unpleasant side effects. There is a great need for more satisfactory treatments. The Company recently submitted its application for Marketing Authorization Application to the Danish authorities. The application to the Danish authorities was accepted for review in February 2023 and is under review at this time.The Company will continue to keep shareholders informed on current developments in a timely manner.

10:00 EDT Jackson Financial falls -19.0% - Jackson Financial is down -19.0%, or -$6.57 to $27.96.

10:00 EDT ProAssurance falls -20.7% - ProAssurance is down -20.7%, or -$3.90 to $14.95.

10:00 EDT MasterBrand rises 20.6% - MasterBrand is up 20.6%, or $1.78 to $10.42.

09:48 EDT Babylon Holdings trading resumes

09:47 EDT Twilio falls -16.1% - Twilio is down -16.1%, or -$8.99 to $47.01.

09:47 EDT Olo rises 14.1% - Olo is up 14.1%, or 96c to $7.79.

09:47 EDT Compass rises 37.7% - Compass is up 37.7%, or $1.05 to $3.85.

09:37 EDT UC San Diego purchases two additional Knightscope K1 Blue Light Towers - UC San Diego, an existing Knightscope customer, purchased two additional emergency phone systems to expand communication capabilities on campus. Knightscope's Blue Light Towers provide a familiar beacon to access reliable communications with public safety professionals in remote locations.

09:32 EDT Canon, Amazon file joint trademark infringement lawsuit - Canon U.S.A., Inc. and its parent company, Canon Inc. of Japan (CAJ), and Amazon.com (AMZN) and Amazon.com Services LLC jointly filed a lawsuit in the United States District Court for the Western District of Washington against 29 selling accounts which sold camera batteries and chargers in the Amazon store, alleging infringement of Canon's trademark rights. "Canon aggressively pursues counterfeiters in the United States and around the world to protect its customers from fake and potentially unsafe products, which unlawfully use the Canon name, as well as to protect the value, trusted reputation, and loyalty that the Canon brand has acquired over decades in producing high-quality, safe, and reliable products. Sales of counterfeit goods on e-commerce websites are increasing in proportion to the growth of the e-commerce market, and Canon and Amazon are collaborating in fighting against counterfeiters and protecting both of our customers. This joint lawsuit was filed as a part of our collaboration."

09:28 EDT 180 Degree Capital issues letter to Comscore preferred shareholders - 180 Degree Capital issued a letter to the preferred stockholders of Comscore, which read in part, "Cerberus, Charter and Liberty Media/Qurate, We trust you are dismayed by the abysmal performance of SCOR's common stock. As SCOR's third largest common shareholder, with approximately 6.0% of the common stock outstanding, we have long shared our constructive views with the SCOR's Board - first privately, and then publicly - about how we believe this Board continues to obstruct operational progress at SCOR from translating into value creation for all stakeholders of the Company. Instead, at every opportunity, it siphons much needed resources from employees and stockholders. We most recently wrote to the Board on April 20, 2023, expressing our demands that: SCOR cease any attempts to pay the Series B annual dividend in additional shares of Series B Preferred Stock; The Compensation Committee reduce director compensation further as, even with the adjustments made this year, it remains egregiously above-market; The Nominating Committee strip Brent Rosenthal of his Lead Independent Director title; and Jon Carpenter be appointed to SCOR's Board. Regrettably, but unsurprisingly given just how tone-deaf this Board has repeatedly shown itself to be, SCOR's Board ignored our suggestions and demands and "buried the story" in a Friday after-market-close filing with the SEC. Of course, if you refuse to engage with shareholders voicing concerns, and are trying to hide this reality, it stands to reason that you would wait until Friday after the close to file with the SEC. This may come as a shock to SCOR's Board, but we and other investors read Friday after-market filings. Nice try. Your representatives on SCOR's Board, which make up a majority of said Board, are sending a clear signal to common stockholders that their voices are of no consequence. The market, in turn, is sending a clear signal of its own, with SCOR's share price falling an additional 13% since the poor decisions mentioned above were disclosed publicly. Delaware law is clear on the subject; it is time for your appointees to SCOR's Board, along with the entire Board, to begin acting as fiduciaries for all stakeholders of SCOR...We, for our part, will not sit idly by and are always available to help where we are able to do so, should you and/or SCOR's Board be interested in engaging constructively with us to create value for all stakeholders. Someone told us a long time ago that we have two ears and one mouth, and that it is best to use them in that proportion. Maybe you should listen a little to the countless suggestions your stockholders have given you over the years and act. We have spoken at length in prior letters, about actions you could take to align yourselves with common shareholders, and yet you have failed to act. We have told you about the obscene Board compensation that your Board has taken for themselves from the employees of the company against the backdrop of a decaying stock price. You haven't addressed it fully. We have told you how outlandish it is for the common shareholders to go to sleep at night knowing that Mr. Rosenthal, who has been an abject failure, is the Lead Independent Director. He is the best you can find for that role? Out of all the people in the world? The situation is numbing, and you have done next to nothing to address any of it. Please take ownership and swift action to remedy what to date has been a colossal failure under your watch. We have invested in this company because of you and what we believe are valuable assets. We expect you will all live up to your reputations for value creation by being infinitely more common shareholder friendly than you have been. For the benefit of the employees that work tirelessly on your behalf, start taking actions that will enhance the equity they own. It would be helpful if you showed some self-awareness for why the stock has declined to less than $1 per share while at the same time having meaningfully higher EBITDA versus two years ago. We are counting on you."

09:21 EDT Informatica 'deepens' partnership with Google Cloud - Informatica (INFA) further strengthened ties with Google Cloud (GOOG, GOOGL))and put more power in the hands of customers with two new developments: the launch of Informatica's Intelligent Master Data Management Software-as-a-Service natively on Google Cloud and Informatica's comprehensive Intelligent Data Management Cloud on Google Cloud in Europe. The announcements were made at Informatica World 2023, the company's annual customer conference underway in Las Vegas. "A key ingredient in Informatica's secret sauce is the breadth and depth of our strategic partnerships, and we couldn't be more pleased to expand our partnership with Google Cloud to bring our industry-leading cloud data management solutions to more organizations," said Jitesh Ghai, Chief Product Officer at Informatica. "With MDM SaaS, our customers can have confidence the data they rely on to inform pivotal business decisions is unified and accurate, while European organizations can solve any data need through the best-of-breed solutions integrated into our single IDMC platform. Informatica helps those in the Google Cloud ecosystem to make sense of their data, to be empowered, and to ultimately bring this data to life."

09:19 EDT NFI Group announces comprehensive refinancing plan - NFI Group announced that it is working to complete a comprehensive refinancing plan to improve financial flexibility, strengthen its balance sheet and best position the Company to capitalize on the historic demand for its products and expected financial recovery. Under the proposed plan, NFI will amend its existing senior secured credit facilities, extend its senior unsecured debt facilities with the Government of Manitoba and Export Development Canada, and raise additional funds through the sale of new common shares and a second lien debt financing. NFI has received confirmation of credit approval from its banking partners for proposed amendments to the Company's existing North American senior secured credit facility and its senior secured UK credit facility. Details of the proposed amendments to the Secured Facilities include the following: The $1.0 billion revolving North American Facility will convert to a $400 million first lien term loan and a $361 million first lien revolving credit facility and the maturity date will be extended from August 2, 2024 to April 30, 2026. The GBP 40 million revolving UK Facility will convert to a GBP 16 million term loan and a GBP 15 million revolving credit facility, and the maturity date will be extended from June 30, 2023 to April 30, 2026. The first lien security interest granted to the lenders under the Secured Facilities will cover all present and future assets of NFI and its subsidiaries. New financial covenants will be in place during the term of the Secured Facilities providing NFI with significant flexibility as the Company continues with its expected financial recovery. The amendments to the Secured Facilities are subject to negotiation of binding documentation and several precedent conditions, including the planned equity sale and second lien debt financing described below. It is possible that certain details relating to the Secured Facilities described herein could change as the documentation relating to those facilities are finalized. The Government of Manitoba and EDC have also both confirmed their intention to extend the maturity of their respective CAD $50 million and $50 million senior unsecured debt facilities to April 30, 2026. EDC has also made available a $100 million guarantee facility to support NFI's surety and performance bonding requirements for new vehicle contracts. As all of the financing transactions are mutually conditional, NFI expects to close all components of the plan at the same time and is targeting completion prior to June 25, 2023. The Company will provide additional details and file the material documents on SEDAR once finalized. However, there can be no assurance that the financing transactions will be completed on the expected terms or at all. On June 25, 2023, the Company's current financial covenant waivers under the Secured Facilities expire and the UK Facility matures. Therefore, if the financing transactions are not completed on or before such date, the Company will need to obtain further extensions, which cannot be assured. With a proposed decrease in the total borrowing capacity under the amended Secured Facilities and to support additional liquidity requirements, NFI plans to raise proceeds of $150 million of equity capital through the sale of new common stock and to raise total gross proceeds of between $200 and $250 million from a second lien debt financing. The second lien debt financing is expected to be on customary market terms for an issuer in these circumstances, which will be finalized during the marketing process. NFI has held detailed discussions with several parties who have expressed significant interest in participating in the equity sale and second lien debt financing. BMO Capital Markets is acting as the Company's financial advisor related to these matters. NFI expects to announce additional details on the planned equity and second lien debt financing in the near-term.

09:11 EDT FSD Pharma announces first patient cohort dosed in Lucid-MS trial - FSD Pharma announced the completion of dosing the first cohort of patients in the Company's Phase I clinical trial of Lucid-21-302, Lucid-MS. The clinical trial being conducted by FSD Pharma through the Company's wholly owned subsidiary Lucid Psycheceuticals, is a first-in-human study evaluating Lucid-MS, a small molecule inhibitor of hypercitrullination, as a novel drug candidate for the treatment of Multiple Sclerosis . "Our clinical development team and international advisory committee are delighted at the progress of this milestone and completing dosing the first cohort," said Dr. Lakshmi Kotra, CEO of Lucid Psycheceuticals. "The safety review committee has recommended to move forward with the next cohort dosing, which we are thrilled

09:08 EDT Bath & Body Works appoints Cooper as Chief Customer Officer - Bath & Body Works (BBWI) announced the appointment of Maurice Cooper as chief customer officer, effective May 22, 2023. In this newly created role, Cooper will be responsible for executing a comprehensive strategy to strengthen and elevate the brand, including growing and retaining Bath & Body Works' passionate customer base through the development of a personalized, connected and compelling end-to-end customer experience. Cooper joins Bath & Body Works from Target (TGT) where he most recently served as senior vice president, marketing - guest and brand experience

09:07 EDT FDA staff say studies don't give 'unambiguous evidence' of SRP-9001 benefit - The FDA has posted briefing documents ahead of the Cellular, Tissue and Gene Therapies Advisory Committee Meeting scheduled for May 12, where advisors will review Sarepta Therapeutics' adeno-associated virus vector-based gene therapy product SRP-9001 for treatment of ambulatory patients with Duchenne muscular dystrophy, or DMD, with a confirmed mutation in the DMD gene. The FDA staff stated in the documents: "Having reviewed nonclinical data and three clinical studies, including a randomized, double-blinded, placebo-controlled trial demonstrating expression of Sarepta's micro-dystrophin at Week 12 following infusion of SRP-9001, FDA notes that the clinical studies conducted to date do not provide unambiguous evidence that SRP-9001 is likely beneficial for ambulatory patients with DMD. It is challenging to conclude with reasonable certainty from the data provided by the Applicant either that SRP-9001 is likely effective for younger patients, or that it is likely ineffective for older patients or those with somewhat poorer functional status. Additionally, FDA has safety concerns related to the possibility of administering an ineffective gene therapy." Reference Link

09:07 EDT Children's Place announces election of all director candidates - The Children's Place announced that shareholders elected all Director candidates to the Company's Board of Directors at its Annual Meeting on May 10, 2023, including new Directors Wes McDonald and Michael Shaffer. Messrs. McDonald and Shaffer, financial and accounting experts with extensive retail experience, will serve on the Audit Committee.

09:06 EDT United Maritime announces agreement to acquire modern Panamax vessel - United Maritime announced that it has entered into a twelve-month bareboat charter agreement for a Japanese-built modern Panamax dry bulk vessel with an unaffiliated third party in Japan. The bareboat charter agreement will commence in the third quarter of 2023 and includes a purchase option for United. The Company has also taken delivery of two previously announced Kamsarmax vessel acquisitions and has secured time charter contracts for both ships that commenced upon the respective deliveries. The Company entered into a twelve-month bareboat charter agreement with an unaffiliated third party in Japan for a 2015-built eco Japanese Panamax dry-bulk vessel of 78,020 dwt. Pursuant to the terms of the bareboat charter, United has advanced a down payment of $3.5 million on signing and will further pay $3.5 million on delivery of the vessel to the Company, which is estimated to take place between July and October 2023, and a daily bareboat rate of $8,000 over the period of the bareboat charter. At the end of the 12-month bareboat period, United has an option to purchase the Vessel for $17.1 million. Vessel Deliveries & Time Charters: The first vessel was built in 2009 at Universal Shipbuilding in Japan, has a cargo-carrying capacity of 81,508 dwt and was renamed M/V Cretansea. The second vessel was built in 2010 at Tsuneishi Zhoushan Shipbuilding, has a cargo-carrying capacity of 82,217 dwt and was renamed M/V Oasea. Stamatis Tsantanis, the Company's Chairman & Chief Executive Officer, stated: "Following the recent, highly profitable sale of three of our tankers, we have re-grown our fleet by acquiring high-quality dry bulk carriers at attractive values. This re-growth of our fleet has been achieved without diluting our shareholders in funding these acquisitions. The new bareboat-in agreement for another modern Panamax vessel strengthens our presence in the sector further, without substantial capital outlay on its delivery, and provides a purchase option at the end of the bareboat period. Moreover, the delivery of two Kamsarmaxes and the prompt commencement of their charters is expected to generate approximately $8 million in gross revenues by the end of the year."

09:04 EDT NeuroOne Medical announces first clinical case using Evo sEEG electrode - NeuroOne Medical Technologies Corporation announced that its first clinical case using the Evo sEEG electrode was performed by Dr. Jamie Van Gompel at Mayo Clinic. Using a non-robotic stereotactic frame system, Evo electrodes were implanted successfully and met the Company's product performance objectives. Dave Rosa, CEO of NeuroOne, commented, "We would like to thank Dr. Van Gompel and his surgical team at Mayo for this 'first in the world' opportunity. We are ecstatic with the initial performance of our Evo sEEG electrodes which confirmed the results of many years of testing on the device. While we previously used the device intraoperatively, this was the first clinical case that was cleared by the FDA for less than 30 day use. We look forward to continued success with the launch of the technology as we continue the roll out of the technology through our distribution partner, Zimmer Biomet."

09:03 EDT LPL Financial: Brennan Hall joins broker-dealer, RIA, custodial platforms - LPL Financial LLC announced that financial advisor Michelle Brennan Hall of Brennan Wealth Advisors, LLC has joined LPL Financial's broker-dealer, RIA and custodial platforms. She reported having served approximately $220 million in advisory, brokerage and retirement plan assets, and joins LPL from FSC Securities Corporation, part of the Advisor Group network. Based in Frisco, Texas, which is surrounded by headquarters of many publicly traded and private companies, Michelle is a veteran wealth advisor with more than 30 years guiding investors' net worth and financial decisions. She started working at her father's wealth management business in 1990 prior to launching her own independent practice-Brennan Wealth Advisors-in 2010. The team has grown to include her husband, Director of Operations Jeff Hall, Director of Portfolio Operations Mary Kloesel and Michelle's son Cameron Hall, a financial analyst, as well as two additional support staff members.

09:02 EDT Caesarstone falls over 6% after results, dividend suspension and guidance - Shares are down 6.4% or 30c per share to $4.40 in pre-market trading.

08:53 EDT CSP Inc. raises quarterly dividend 33% to 4c per share - The company also announced that its Board of Directors has declared a 33% increase in the quarterly dividend, from $0.03 per share to $0.04 per share payable June 13, 2023 to shareholders of record on the close of business on May 25, 2023.

08:46 EDT Occidental Petroleum sees FY23 total company production 1.17-1.22 Mboed - Previous guidance was 1.15-1.21Mboed. Sees FY23 Oxychem pretax income $1.4B-$1.6B vs. previous guidance of $1.3B-$1.6B. Sees FY23 total company capital budget $5.4B-$6.2B, in line with previous guidance.

08:42 EDT Metallic Minerals announces $6.3M equity investment by Newcrest Mining - Metallic Minerals announced a strategic equity investment by a wholly-owned subsidiary of Newcrest Mining Limited in the form of a non-brokered private placement, with the goal of advancing the Company's La Plata copper-silver-gold-platinum group element alkalic porphyry project in Colorado, USA. Pursuant to the private placement, Newcrest will complete a financing of $6.34 million, consisting of 15,838,593 units of Metallic Minerals at a price of $0.40 per unit, with each unit comprising one common share and 0.75 of a common share purchase warrant. This represents a 13% premium to the 20-day volume weighted average price of Metallic Minerals' shares on the TSX-V on May 9, 2023. Each full warrant shall entitle Newcrest to purchase one common share at an exercise price of $0.55, providing $6.5 million in additional funding, if exercised. The warrants shall be exercisable for three years from the date of issue and contain a customary acceleration provision, which shall be effective if the common shares trade for a period of 20 consecutive trading days at or above $0.825 on the TSX-V. Following closing of the investment, Newcrest will hold 9.5% of the issued and outstanding common shares of Metallic Minerals on a non-diluted basis and, including the warrants, 15.5% of the issued and outstanding common shares on a partially diluted basis. In connection with the private placement, Metallic Minerals and Newcrest have entered into an investor rights agreement, pursuant to which Newcrest will be entitled to certain customary rights including participation in future equity issuances and a right to maintain its pro-rata position in the Company. Newcrest and the Company have also agreed to certain customary standstill and transfer restrictions. In addition, a technical committee will be formed with representatives from Metallic and Newcrest, providing access to Newcrest's substantial technical expertise in similar alkalic porphyry systems and underground bulk-tonnage, block-cave mining operations. Newcrest shall also have a right to appoint a director to Metallic Minerals' board, upon exercise of the private placement warrants, if they hold at least 13% of the issued and outstanding shares of the Company.

08:38 EDT Laser Photonics adds three sales executives as part of investment plan - Laser Photonics announced it has hired three sales executives as part of its investment plan announced on April 17, 2023. "Hiring key account managers in our core verticals is critical for us to grow sales in 2023 and beyond," said Peter Evans, president, Laser Photonics. "These three individuals that we brought onboard have extensive experience and contacts working in the defense, automotive and energy verticals, which are among the largest target markets for our CleanTech laser cleaning systems. I'm excited to see these new hires hit the ground running, and we will continue to identify additional candidates to address other key vertical opportunities in the months to come."

08:36 EDT Treasure Global integrates chatbot feature into ZCITY App - Treasure Global announced the integration of artificial intelligence with a user friendly chatbot powered by Treasure Global's data analysis engine and ChatGPT into its proprietary ZCITY App. With the chatbot feature ZCITY users will be able to ask questions for recommendations of restaurants, shopping, and more. Using its advanced AI-powered technology engine, Treasure Global will undertake comprehensive data compilation and analysis of user behavior through review of users' spending patterns, including scanned receipts. "Treasure Global is continuously innovating our digital platforms to provide users with best-in-class, targeted and easy solutions for their lifestyle needs," said Sam Teo, Chief Executive Officer of Treasure Global. "As a next step in the evolution of ZCITY, we are now pleased to integrate AI in the app with a chatbot powered by our data analysis engine and ChatGPT. The new feature will provide benefits for both users and merchants, through tailored restaurant recommendations, rewards with scanned receipts and critical data capturing on consumer behavior, overall improving accuracy and relevance of interactions. In addition, Treasure Global will enhance its data collection which will provide the necessary insights for us to continue developing new and improved functionalities for our solutions."

08:35 EDT Adial Pharmaceuticals receives notice of exercise from Adovate - Adial Pharmaceutical announced that Adovate has provided irrevocable notice of exercise of its previously announced option to acquire the assets and business of Purnovate, Inc., a wholly owned subsidiary of the Company, under the terms previously agreed. Adovate was recently formed by William Stilley, co-founder and former CEO of Adial, for the sole purpose of acquiring, funding and advancing Purnovate's business. The option exercise is effective May 16, 2023. With the notice, Adial received a non-refundable option exercise fee and upfront payment of $450,000, and, after a final acquisition agreement is signed, will receive expense reimbursement of approximately $0.9 million for Purnovate expenditures incurred and paid by Adial after December 1, 2022 through and including May 15, 2023. Any Purnovate expenses incurred on and subsequent to May 16, 2023, will become the responsibility of Adovate. In addition, the Company is entitled to receive up to approximately $11 million in development and approval milestones for each compound, as well as a total of $50 million in additional commercial milestones, for a total consideration of up to $83 million with potential milestone payments on additional compounds. Additionally, the Company will receive a single digit royalty and receive a 19.9% equity stake in Adovate. Using the Purnovate adenosine drug development platform, Adovate intends to focus on inventing and developing best-in-class adenosine receptor agonists and antagonists. The adenosine receptors have been associated with a broad range of disease classes, including pain, oncology, addiction, pulmonary, inflammation and others. Historically, the majority of adenosine compounds have been limited to a nonclinical setting due in part to inadequate solubility profiles that limit their distribution to the target tissue. The Purnovate technology is designed to address this limitation by delivering substantially improved biodistribution. These next-generation compounds have already demonstrated preclinical efficacy and are being advanced towards clinical studies. The transaction was independently evaluated and unanimously approved, first by the Adial Audit Committee of the Board of Directors, and then by its full Board of Directors, with Mr. Stilley, a current board member, abstaining from the vote.

08:33 EDT Milestone Scientific completes first series of ESI using CompuFlo - Milestone Scientific announced the successful completion of the first series of epidural steroid injections, ESI, using the CompuFlo Epidural System by physicians under the new American Medical Association, AMA, Current Procedural Terminology, CPT, guidelines for AI-assisted analgesic epidural needle placement in patients. The AMA's new technology-specific Category III CPT code, which came into effect in the CPT codebook on January 1, 2023, specifically covers technologies that "integrate AI to place an epidural needle." The published and copyrighted guidelines further note that the technology must include real-time software to assist the physician by transmitting key data points, along with sensors to interpret epidural pressures, detail anatomical needle placement, and measure precise saline volume via software facilitating data transmission to an epidural system console screen. Arjan Haverhals, CEO and President of Milestone Scientific, stated, "We are proud to announce that multiple physicians have now completed ESI procedures using the CompuFlo Epidural System under the new AMA CPT guidelines for AI-assisted epidural needle placement. This is an important milestone, as it further validates the medical importance of the CompuFlo Epidural System by these physicians in their plans of treatment. Specifically, our proprietary and highly accurate AI-assisted technology enhances both the efficacy and safety of pain management surgery. We believe this data will play an important role as we seek reimbursement for the CompuFlo Epidural System under the new CPT(R) code."

08:31 EDT T. Rowe Price reports preliminary AUM $1.35T at April 30 - T. Rowe Price Group reported preliminary month-end assets under management of $1.35T as of April 30. Preliminary net outflows for April were $3.7B.

08:29 EDT Pieris Pharmaceuticals expects cash to fund operations for over 12 months - Cash, cash equivalents, and investments totaled $48.4 million for the quarter ended March 31, 2023, compared to a cash and cash equivalents balance of $59.2 million for the year ended December 31, 2022. The decrease was due to funding operations in the first quarter of 2023. The Company believes operations are sufficiently funded for more than the next 12 months.

08:24 EDT Teva sees first payment for U.S. opioid settlement in 2H23

08:19 EDT Minerva announces update on NDA for roluperidone - Minerva Neurosciences announced that on May 8, 2023, it received confirmation from the U.S. Food and Drug Administration, FDA, that the Company's New Drug Application, NDA, for roluperidone for the treatment of negative symptoms in patients with schizophrenia has been filed in accordance with the recent Appeal Granted letter dated April 27, 2023 and assigned a standard review classification. The FDA has assigned a Prescription Drug User Fee Act, PDUFA, goal date of February 26, 2024. The FDA advised that it identified potential review issues that had been previously cited in the refuse-to-file decision letter, which included those discussed at the Type C meeting in March 2022. "The filing of the NDA is an important event for Minerva and a step forward to our goal to treat those patients suffering negative symptoms of schizophrenia. If approved, we believe roluperidone could be an important new option to address the serious unmet need faced by that group of patients with schizophrenia whose negative symptoms are a major source of disability and adversely impact their daily quality of life," said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva.

08:18 EDT Bank of America opens new branch in Luxembourg - Bank of America announced that it has opened a new branch in Luxembourg, further strengthening its capabilities and the value it offers to clients in core markets.The launch means the bank can support clients - corporate, commercial and NBFIs, with setting up local bank accounts and provide in-country transaction banking products and services. In particular, as Luxembourg is the second largest investment fund centre in the world1, after the United States, the bank will deepen its global cash management services to these NBFIs. Fernando Vicario, CEO of Bank of America Europe DAC said, "This announcement marks a significant milestone for businesses in the region. Many multi-national companies have chosen Luxembourg as a European hub for their activities and we are proud to support business opportunities and responsible growth in this important financial centre

08:17 EDT FuelCell adjourns Annual Meeting of Stockholders to May 22 - FuelCell Energy has announced that its Annual Meeting of Stockholders has been adjourned until May 22, 2023 at 1:00 p.m. EDT in order to solicit additional proxies and allow stockholders additional time to vote on the proposals set forth in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission on February 17, 2023. At that time, the Annual Meeting will be reconvened to vote on the proposals described in the 2023 Proxy Statement/ As of May 8, 2023, the Company has received proxies representing a sufficient number of votes to elect each of the director nominees named in the 2023 Proxy Statement and to approve Proposals 2, 3, and 4, but the Company has not received proxies representing a sufficient number of votes to approve Proposal 5. Approval of Proposal 5 requires the affirmative vote of the holders of a majority of the shares of our common stock outstanding as of the record date for the Annual Meeting. This means that Proposal 5 requires a greater number of votes for approval than the other proposals described in the 2023 Proxy Statement. As of May 8, 2023, of the 405,732,053 shares of our common stock outstanding as of the record date for the Annual Meeting, 227,692,874 have voted on Proposal 5. Of these votes, more than 80% were votes FOR Proposal 5. FuelCell Energy is urging all stockholders to vote immediately for Proposal 5, which would allow FuelCell Energy to increase the number of authorized shares of common stock, providing the Company with needed flexibility to issue shares in the future to take advantage of market conditions or favorable opportunities. As FuelCell Energy has a diverse stockholder base with many investors, every vote received is meaningful.

08:17 EDT SP Plus deploys Sphere technology solutions for Richmond, Virginia - SP+ Corporation announced a technology overhaul for the City of Richmond, Virginia, to Sphere, a technology platform that spans the company's industry-leading suite of solutions. Sphere supports the SP+ commitment to delivering enhanced end-to-end mobility solutions, from customer acquisition and purchases to operational logistics and data reporting. "The amazing technology provided by SP+ has greatly improved our facility at 7th and Marshall," said Lynne Lancaster, Public Works Deputy Director, City of Richmond. "We are seeing an increase in transactions, as well as a significant boost in revenue. The City of Richmond greatly appreciates the operational expertise of SP+, and having them as our single-source provider is extremely efficient on our-end."

08:15 EDT Teva CEO: Still unclear when Teva will be able to launch Humira biosimilar

08:15 EDT Red White & Bloom Brands requires additional time to complete Annual Filings - Red White & Bloom Brands is providing an update on the timing of filing the audited annual financial statements, accompanying MD&A and annual certificates for the period ended December 31, 2022. The Company reports that it will require additional time to complete the Annual Filings, from its previously reported expectation to file by end of day on May 9, 2023. The Company and its Auditors continue to work collaboratively to ensure compliance with the aforementioned disclosures on an expedient basis. RWB will issue a news release announcing completion of the Annual Filings once posted to SEDAR. The Company anticipates that the cease trade order will be revoked within a few days after the required filings are made.

08:14 EDT Impel Pharmaceuticals announces appointment of Kalb as CFO - Impel Pharmaceuticals announced the appointment of Michael Kalb, CPA, as Chief Financial Officer, CFO, effective May 10, 2023. Kalb has more than 30 years of experience in the pharmaceutical and financial service industries. Prior to joining Impel Pharmaceuticals, he was Executive Vice President & Chief Financial Officer of CinCor Pharma.

08:10 EDT Endava announces acquisition of Mudbath, Australia, no terms - Endava announced the acquisition of Mudbath & Co. Pty Ltd, headquartered in Newcastle, Australia . Mudbath is an Australian-based technology firm specializing in strategy, design and engineering services. Mudbath partners with businesses to build new digital solutions, enhance user experiences and accelerate digital transformation programs across enterprise systems, web and mobile products using their proven agile delivery methodology. Mudbath's clients span broad industry verticals, including retail, mining , health, insurance, banking and travel. Mudbath's employees are based primarily in Newcastle, Sydney and Melbourne, Australia. The acquisition of Mudbath follows Endava's organic entry into the Australia market in 2021 and acquisition of Lexicon in 2022, and further enhances Endava's depth and breadth in Australia. Endava continues to see Australia as a growing and attractive market with strong demand for high-quality technology product creation delivered both onshore and nearshore by multidisciplinary delivery teams. Mudbath's teams and strong client relationships are expected to complement Endava's expanding nearshore capability in Malaysia and Vietnam to continue to deliver innovative, high-quality, digital solutions.

08:09 EDT Teva CEO Francis: Company is underappreciated currently - Comments taken from Q1 earnings conference call.

07:57 EDT Allkem, Livent to combine in all-stock merger of equals - Allkem (OROCF) and Livent (LTHM) announced the signing of a definitive agreement to combine the two companies to create a leading global lithium chemicals producer. The Transaction is expected to close by the end of calendar year 2023, and upon closing of the all-stock merger of equals, Allkem shareholders will own approximately 56% and Livent shareholders will own approximately 44% of NewCo. Allkem and Livent, two global lithium chemicals companies, will combine their highly complementary range of assets, growth projects, and operating skills across extraction and processing under a vertically integrated business model with the scale and expertise to meet the rapidly growing demand for lithium chemical products. The combined company will have a significant footprint of low-cost assets diversified across key geographies, products, and customers. Given the proximity of certain assets in Argentina and Canada, significant cost synergies and capex savings, in addition to other anticipated commercial synergies, are expected to be realized from the opportunity to co-develop and de-risk future expansion projects and operations. The combination is expected to create substantial value for the shareholders of both companies through: Value creation from the synergistic combination and close proximity of assets, with additional synergies expected beyond CY'27E; Estimated run-rate operating cost synergies of approximately US$125 million per annum from SG&A, asset optimization, and logistics and procurement savings. A significant portion of the synergies are expected to be realized through removing duplicate costs, improvement of procurement, site management, transport, and logistics functions at Sal de Vida, Hombre Muerto, and Quebec, and through closer integration of operations. The majority of the annual run-rate pre-tax operating cost synergies are expected to be realized within three years; Further synergies are expected to be realized from the sharing of technological expertise, improved flexibility in product flows, plant optimization, and enhanced marketing efficiencies; In addition to operating synergies, NewCo is expected to realize approximately US$200 million in one-time capital expenditure savings, driven by the consolidation of shared infrastructure, streamlining construction and procurement, and leveraging complementary engineering work at Hombre Muerto and Sal de Vida, as well as at a co-located spodumene to hydroxide facility processing materials from the Quebec spodumene resources. Transaction metrics: Exchange ratio determined based on each Company's estimated relative contribution to risk-adjusted net asset value; Transaction is expected to be immediately accretive to both Livent's and Allkem's shareholders on a NAV per share basis, reflecting the material synergies expected to be realized from the Transaction; The transaction results in Allkem shareholders owning approximately 56% of NewCo compared to 53% implied by the volume weighted average share prices over a one-month period. Stronger financial profile positions the combined entity to deliver growth. Strong balance sheet with combined liquidity of US$1.4 billion and limited indebtedness. Positive cash flow generation provides the financial strength needed to accelerate the growth strategy. Greater liquidity for investors and more diversified shareholder base. Greater liquidity for investors through a primary listing on the New York Stock Exchange and a foreign exempt listing on the Australian Securities Exchange via CHESS Depository Interests. Seeking US index inclusion on implied combined market capitalization and pro-rata CDI inclusion in the S&P / ASX 200 index. Tax-free all-stock transaction: Share for share exchange transaction expected to be a tax-free transaction for shareholders. NewCo will have a primary listing on the NYSE and maintain a foreign exempt listing on the ASX. Under the terms of the Transaction, existing Allkem shareholders will receive one NewCo ASX listed CDI for each Allkem ordinary share held, except for shareholders in certain ineligible jurisdictions, who will receive cash proceeds from the sale of the NewCo CDIs in lieu of such CDIs after closing. Under the Merger, Livent shareholders will receive 2.406 NewCo NYSE listed shares of common stock for each Livent share held. Following the Transaction, Allkem and Livent shareholders are expected to own approximately 56% and 44% of the combined company, respectively. The Transaction Agreement and the Transaction have been unanimously approved by the Board of Directors of each company, and in the case of Allkem, subject to the Independent Expert concluding, and continuing to conclude, that the Scheme is in the best interest of Allkem shareholders. The combined company will benefit from proven and experienced business leaders at both the Board and executive levels, along with diverse, high-performing teams at NewCo's operating sites. NewCo is to be incorporated in the Bailiwick of Jersey, with corporate headquarters to be in North America, with the exact location and company name to be announced at a later date, and corporate residency to be in Ireland. Upon completion of the Transaction, Peter Coleman will become the Chairman of NewCo, Paul Graves will become the CEO of NewCo, and Gilberto Antoniazzi will become the CFO of NewCo. The NewCo Board will have 14 members, consisting of 7 directors designated by Allkem and 7 directors designated by Livent. The commercial, operational, and capital deployment teams will be comprised of representatives from both companies. Allkem CEO, Martin Perez de Solay, will provide consulting services to NewCo to help facilitate a smooth integration process post transaction close. Closing of the Transaction is subject to the satisfaction or waiver of customary closing conditions, including receipt of regulatory approvals, approval by both Livent and Allkem shareholders, the Independent Expert concluding that the Scheme is in the best interest of Allkem shareholders and not changing, withdrawing, or qualifying that conclusion, tax opinion delivery, and Australian tax class ruling confirmation, and Australian Court approval. Subject to the satisfaction or waiver of the conditions to closing, the Transaction is expected to close by the end of calendar year 2023.

07:55 EDT Teva taking proactive measures to address challenges around COGS management - Comments taken from Q1 earnings conference call presentation slides.

07:52 EDT Stack Capital reports book value per share of $11.22 as of March 31 - "It's extremely encouraging to see our existing portfolio companies continue to grow and flourish in the current economic environment," said Jeff Parks, CEO of Stack Capital. "The investing landscape for growth to late-stage private businesses also continues to become more attractive by the day for Stack Capital, which has a significant amount of cash available to deploy across quality, high-growth companies, at reasonable valuations. In addition to targeting preferred shares which provide added downside protection, we'll seek to benefit from of other investor-friendly terms such as IPO ratchets and liquidation preferences with future investment opportunities." The Company's cash position as at March 31, 2023, was $30.2 million or $3.33 per share.

07:50 EDT Pipestone Energy CEO Paul Wanklyn takes leave of absence - Pipestone Energy announced that Paul Wanklyn, President and Chief Executive Officer, will be taking an immediate leave of absence for health reasons. Pipestone's Board of Directors has appointed Dustin Hoffman, the Company's Chief Operating Officer, as Interim President and Chief Executive Officer, effective immediately.

07:50 EDT G1 Therapeutics announces new results from Phase 2 trial of trilaciclib - G1 Therapeutics presented preliminary results from 30 patients enrolled in its ongoing Phase 2, single arm study of trilaciclib administered prior to the antibody-drug conjugate, ADC, sacituzumab govitecan-hziy in patients with unresectable locally advanced or metastatic triple-negative breast cancer, TNBC. These data highlight the potential for trilaciclib to meaningfully reduce adverse events related to use of sacituzumab. As expected, patients with PD-L1(+) tumors appear to respond earlier than patients with PD-L1(-) tumors. The Company expects to reach the overall survival endpoints in the first quarter of 2024. Data generated across multiple preclinical and clinical studies to date show that trilaciclib has the greatest effect on longer term endpoints including OS rather than earlier efficacy measures such as ORR and progression free survival, consistent with other immunotherapies like checkpoint inhibitors. "These preliminary results continue to show the consistent benefit of trilaciclib when administered prior to sacituzumab, relative to the previously published single agent safety profile of this ADC, including greater than 50 percent reductions in the incidence of events including neutropenia, anemia, and diarrhea," said Raj Malik, M.D., Chief Medical Officer at G1 Therapeutics. "It is too early to determine the efficacy of trilaciclib prior to sacituzumab in this patient population. However, early indications suggest a higher response rate in patients with PD-L1 positive tumors, which commonly have an immune inflamed tumor microenvironment and are thus more likely to respond early to immunotherapies. Given that this trial includes a heavily pretreated patient population, we are enthusiastic about these data to date. We will continue to monitor efficacy to assess the potential of trilaciclib to improve overall survival - by protecting the immune system and stimulating long term immune surveillance - when combined with additional treatment regimens beyond gemcitabine/carboplatin for patients with TNBC. We look forward to these overall survival data in the first quarter of 2024."

07:47 EDT Marathon Gold, Miawpukek First Nation enter into socio-economic agreement - Marathon Gold and Miawpukek First Nation announce that they have concluded a Socio-Economic Agreement, SEA, concerning the development of the Valentine Gold Project, located in central Newfoundland. The Agreement was signed by Matt Manson, President and CEO of Marathon, and Miawpukek Chief Mi'sel Joe and representatives of the Miawpukek Band Council. Matt Manson, President and CEO, commented: "The investment in people and Indigenous communities is an important component of the development of Newfoundland and Labrador's rich mineral resource potential. These SEA agreements are the first of their type for mining businesses on the island of Newfoundland, and they reflect our commitment to prioritize Indigenous economic development, employment, and community well-being. Under Chief Mi'sel Joe's leadership, Miawpukek First Nation has become a dynamic and flourishing part of Newfoundland's economic and cultural life, and we look forward to a long and productive relationship as we move forward with the development and operation of the Valentine Gold Project."

07:47 EDT Alterity Therapeutics reports cash balance of A$21.9M as of March 31 - "We continue to make excellent progress with our ATH434 Phase 2 clinical trial in participants with early-stage Multiple System Atrophy, a rapidly progressing Parkinsonian disorder with no approved treatment," said David Stamler, M.D., Chief Executive Officer, Alterity. "The Phase 2 trial is gaining momentum with active recruitment in five countries, including the United States. We were pleased that an independent study was published providing further evidence that ATH434 has potential to be neuroprotective in humans." The Company's cash position on 31 March 2023 was A$21.9M with operating cash outflows of A$4M.

07:46 EDT Jacobs, Cirba Solutions expand sustainable battery processing in U.S. - Jacobs announced that it was selected by Cirba Solutions, a battery materials and management company for end-of-life batteries and gigafactory scrap, to expand manufacturing capacity for sustainable electric vehicle battery materials across North America. Jacobs is managing the facility design and supporting construction of multiple site locations, including an expansion at Cirba Solutions' lithium-ion processing site in Lancaster, Ohio. The expansion project is estimated at $200M, and the site recently received over $82M in grants from the U.S. Department of Energy.

07:44 EDT Boralex reports growth of project portfolio in Q1 - Highlights: Addition of 238 MW of wind and solar projects and 230 MW of storage projects to the early stage of the project portfolio in the first quarter of 2023: Wind projects in Europe totalling 117 MW. Solar projects in the United States and Europe totalling 121 MW. Storage projects in Ontario totalling 230 MW. Production up 1% compared to Q1-2022 due to assets commissioning and favourable wind conditions in France which offset unfavorable wind conditions in Canada. The increase on a Combined basis comes from the integration of the wind farms acquired in the United States in late 2022, production 1% above anticipated for Q1: Wind: up 4 % from Q1-2022 and equal to anticipated production for Q1. Hydroelectric: up 10% from Q1-2022 and 18% above anticipated production for Q1. Solar: down 12% from Q1-2022 and 3% below anticipated production for Q1. EBITDA for the first quarter of 2023 down 1% and operating income down 16% from the same quarter of 2022; EBITDA of $171 million in Q1-2023, down $2 million from Q1-2022. EBITDA for the first quarter of 2022 included an amount of $16 million attributable to certain contracts for which Boralex had to record a provision in Q3-2022 following the implementation of the 2022 Supplementary Budget Act in France. Operating income of $77 million ($106 million) for Q1-2023, down $14 million from Q1-2022. Higher net cash flows related to operating activities but lower discretionary cash flows in Q1-2023 Net cash flows related to operating activities of $244 million in Q1, up $107 million from Q1-2022. Cash flows from operations4 of $141 million in Q1, $5 million higher than in Q1-2022. Discretionary cash flows of $65 million in Q1, down $12 million from Q1-2022. As indicated for EBITDA, cash flows for Q1-2022 included an additional $16 million attributable to certain contracts in France. Sustained financial flexibility and balance sheet strength More than $330 million in available cash resources and authorized financing facilities4 as at March 31, 2023. An amount of $77 million under the revolving credit facility will be transferred to the letter of credit facility guaranteed by Export Development Canada, which was increased by $125 million bringing its total authorized amount to $200 million in April 2023. Net debt to total capitalization ratio of 38% as at March 31, 2023, compared to 40% at the end of 2022.

07:43 EDT Universal Stainless announces base price increase of 5%-10% on bar products - Universal Stainless & Alloy Products announced a base price increase of 5% to 10% on bar products. The increase goes into effect immediately. Current material and energy surcharges will remain in effect. Brian Kane, Vice President Sales & Marketing, commented, "We continue to experience cost increases across all areas of our business, and it is necessary for us to adjust our pricing to keep up with this higher cost burden. We will continue to take the actions necessary to maintain our industry leading customer service and exceptional production quality standard."

07:42 EDT Rivian Automotive CEO says Amazon partnership still exclusive - CEO RJ Scaringe is speaking on CNBC.

07:41 EDT Chart Industries, Crane test a new liquid hydrogen valve - Chart Industries (GTLS) and Crane Company (CR) have successfully tested a new cryogenic valve designed and built by Crane for liquid hydrogen applications. This is the first valve launched from Crane's CRYOFLO line of bellow seal vacuum jacketed globe valves, designed and tested by Crane, with final validation, review, and testing conducted by Chart. Final testing was conducted at Chart's one-of-a-kind liquid hydrogen test facility in New Prague, MN, USA, leveraging Chart's 60 years of experience with hydrogen equipment and the facility's availability of the extremely cold cryogenic liquid for testing. The testing confirms that Crane's CRYOFLO liquid hydrogen valve design can operate safely and reliably at extremely low temperatures, while supporting best-in-class high-flow rates at low-pressure drop as designed. Notably, CRYOFLO is the first valve Chart has successfully completed a liquid hydrogen endurance test in a high-cycle application. Testing included installing Crane's valve in a validation system provided by Chart that flowed liquid hydrogen through the valve at varying operating temperatures and pressures. The valve successfully endured well over 5,000 open/close cycles at a pressure of 150 psig/10 bar, and it required no adjustments or maintenance during the test.

07:39 EDT Syros Pharmaceuticals sees existing cash/equivalents sufficient into 2025 - Based on its current plans, Syros believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its anticipated operating expenses and capital expenditure requirements into 2025, beyond pivotal Phase 3 data from the SELECT-MDS-1 trial and initial data from the randomized portion of the SELECT-AML-1 trial.

07:32 EDT Triumph Group, Moog enter 787 MRO agreement - Triumph Group (TGI) and Moog have entered into a five-year agreement to provide maintenance, repair and overhaul solutions for Boeing (BA) 787 landing gear and cargo door actuation control systems through the Moog Total Support Program for an Asia Pacific operator who has more than 40 Boeing 787's in service. This work will be performed at Triumph Actuation Products & Services facilities in Clemmons, North Carolina and Yakima, Washington.

07:27 EDT Caesarstone suspends FY23 revenues or adjusted EBITDA margin guidance - Based on the actions and initiatives underway, the Company has amended its full year outlook to align with its focus on cash flow. With headwinds such as slow macroeconomic conditions and volatile business trends, which may be offset by tailwinds that include lower raw material and shipping costs and restructuring efforts, the Company is no longer providing an outlook for full year revenues or Adjusted EBITDA margin. The Company will prioritize cash flow and expects to generate positive cash flow from operations and end the year with an improved net cash position based on inventory reductions and other working capital improvements, along with cost optimization efforts.

07:26 EDT MasterBrand board approves new $50M buyback

07:23 EDT iTeos Therapeutics expects cash to provide runway into 2026 - The company's cash, cash equivalents, and investments position was $706.6 million as of March 31, 2023, as compared to $824.0 million as of March 31, 2022. The company continues to expect its cash balance to provide runway into 2026.

07:16 EDT Verano Holdings sees 2023 FCF $50M-$75M - The Company reiterates its guidance of $50-75 million in Free Cash Flow and tightens its range of Capital Expenditure guidance to $35-50 million.

07:14 EDT Vigil Neuroscience expects cash to fund operations into 1Q25 - Cash, cash equivalents, and marketable securities were $164.5 million as of March 31, 2023, compared to $186.6 million as of December 31, 2022. The Company expects its cash, cash equivalents and marketable securities to fund its operational plans into the first quarter of 2025.

07:11 EDT Advantage Solutions sees 2023 adjusted EBITDA $400M-$420M - The Company is reiterating its guidance for fiscal 2023 with Adjusted EBITDA anticipated to range from $400 million to $420 million.

07:10 EDT Aecom joint venture with Aurecon awarded contract for tunnel in Sidney - AECOM announced that its joint venture with Aurecon has been awarded a contract by Acciona Construction Australia for the detailed design of the Western Harbour Tunnel, which will create a bypass of the Sydney central business district. Following the acceptance of an alternative client reference design, the AECOM joint venture will deliver a detailed design of the Western Harbour Tunnel that avoids dredging by utilizing tunnel boring machines instead of an immersed tube tunnel. The new 6.5-kilometer Western Harbour Tunnel is expected to cut traffic by 35% in the Western Distributor, 20% in the Sydney Harbour Tunnel, and 17% on the Harbour Bridge.

07:08 EDT Ceva acquires RealSpace 3D Spatial Audio from VisiSonics - CEVA announced the acquisition of the RealSpace 3D Spatial Audio business, technology and patents from VisiSonics. Based in Maryland, close to CEVA's sensor fusion R&D development center, the VisiSonics spatial audio R&D team and software extend the Company's application software portfolio for embedded systems, bolstering CEVA's strong market position in hearables, where spatial audio is fast becoming a must-have feature. Spatial audio will also drive innovation in many other end markets, including gaming, AR/VR, audio conferencing, healthcare, automotive and media entertainment, all which CEVA can further address following this acquisition. Future Market Insights estimates that the market for 3D audio will grow 4.1X from 2022 to 2032, reaching nearly $31.9B in 2032. RealSpace spatial audio rendering software provides an accurate digital simulation of real-life, immersive sound.

07:06 EDT GFL Environmental announces TSX acceptance of NCIB - GFL Environmental announced that the Toronto Stock Exchange has accepted the company's notice of intention to renew its normal course issuer bid, or NCIB, for the 12-month period commencing on May 12 and ending no later than May 11, 2024. The NCIB will be conducted through the facilities of the TSX and the New York Stock Exchange or alternative Canadian trading systems, if eligible.

07:05 EDT Finch Therapeutics expects cash to fund operations into 2025 - Finch's cash and cash equivalents as of March 31, 2023 were $41.7 million, compared to $71.0 million as of December 31, 2022, which reflects, among other things, Finch's payment of $16.2 million in January 2023 to fully satisfy the Company's obligations under its loan agreement with Hercules Capital, Inc. Finch believes its cash and cash equivalents on hand as of March 31, 2023 will be sufficient to fund its operating expenses and capital expenditures into 2025.

07:02 EDT Wendy's reports Q1 U.S. same-restaurant sales growth 7.2% - Reports Q1 International same-restaurant sales growth of 13.9%; Global 8%.

06:48 EDT Syneos Health to be acquired by private investment consortium for $7.1B

06:44 EDT AstraZeneca's Ultomiris approved in EU for adults with NMOSD - Ultomiris has been approved in the European Union as "the first and only long-acting C5 complement inhibitor" for the treatment of adult patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, or NMOSD, AstraZeneca announced. Reference Link

06:36 EDT Transocean Equinox awarded $137M five-well contract in Australia - Transocean announced that the Transocean Equinox was awarded a five-well contract in Australia by a major operator, representing approximately $137M in firm backlog, excluding full payment for mobilization and a demobilization fee. The estimated 300-day contract is expected to commence in the first quarter of 2024. The contract also provides for a one-well option, potentially keeping the harsh environment semisubmersible in Australia through the Q1 of 2025.

06:28 EDT Chiesi, Protalix announce FDA approval for Elfabrio - Chiesi Global Rare Diseases and Protalix BioTherapeutics announced that the FDA has approved Elfabrio in the United States for the treatment of adult patients with Fabry disease.

06:12 EDT Babylon Holdings plans to implement a take private transaction - Babylon Holdings is pleased to announce that it has entered into an amendment and restatement of its senior secured term loan facility with AlbaCore Capital LLP and certain of its affiliates, dated March 9, for up to an additional $34.5M in funding. This investment demonstrates AlbaCore's ongoing support to Babylon. The Interim Funding will be provided on similar pricing terms to the original Bridge Facility Agreement. The Interim Funding will provide liquidity to support Babylon's operations and enable Babylon to proceed with a proposed longer-term funding and take-private solution under a framework implementation agreement entered into between Babylon and AlbaCore. Under the Framework Agreement, Babylon and AlbaCore expect to proceed with a restructuring and recapitalization that will strengthen Babylon's balance sheet and provide additional liquidity to deliver on Babylon's strategic plan. The Framework Agreement contemplates that core operating subsidiaries of Babylon Holdings Limited will return to private ownership and is expected to provide, subject to specified terms and conditions and definitive documentation, for: (i) additional funding for the Go-Forward Business; (ii) an amendment of the existing aggregate debt under the original $300 million principal amount of AlbaCore notes due 2026, the notes issued under the Bridge Facility Agreement, and the Interim Funding, including an extension of the maturity of the Debt; and (iii) a new long-term employee incentive plan. Babylon's Board of Directors has approved the Interim Funding and the Take Private Proposal as a constructive step to deliver a longer-term solution to support the Go-Forward Business's continued path toward profitability, upon consideration of the results of Babylon's previously announced efforts to explore strategic alternatives, including additional financing and a possible sale of the Meritage Medical Network/Independent Physician Association business. The Interim Funding will be made available to Babylon in May and early June 2023, subject to the satisfaction of certain conditions precedent. Babylon and AlbaCore plan to implement the Take Private Proposal during June in the absence of other acceptable transaction proposals from third parties in the interim period. It is expected that as part of the implementation of the Take Private Proposal, Babylon Holdings Limited will sell Babylon Group Holdings Limited, which owns Babylon's core operating subsidiaries that will comprise the Go-Forward Business, to a newly formed entity capitalized by AlbaCore and other investors. This sale will occur without the approval of or any payment to Babylon Holdings Limited's Class A ordinary shareholders or other equity instrument holders, as AlbaCore will be exercising rights under its debt agreements with Babylon.

05:35 EDT Addex Therapeutics announces IRC recommendation to continue ADX71149 trial - Addex Therapeutics (ADXN) announced that the ADX71149 Phase 2 epilepsy clinical study has been recommended to continue by an Independent Interim Review Committee, or IRC, following review of unblinded data from Part 1 of patient Cohort 1. The clinical study is being conducted by Janssen Pharmaceuticals of Johnson & Johnson (JNJ). "The recommendation of the IRC and the decision of our collaboration partner to continue the study is very encouraging and suggests ADX71149 is potentially safe and well tolerated and may have a positive impact on this patient population," said Tim Dyer, CEO of Addex. "We look forward to providing further updates on the progression of this important clinical study in the second half of this year."

05:26 EDT Zealand Pharma announces BI 456906 trial met primary endpoint - Boehringer Ingelheim and Zealand Pharma announced that patients treated with BI 456906 achieved up to 14.9% weight loss after 46 weeks, using the planned maintenance dose. The phase II clinical trial evaluating the effect of different doses of the novel glucagon/GLP-1 receptor dual agonist BI 456906 in people living with obesity or overweight without type 2 diabetes met its primary endpoint. These results including an analysis of the actual maintenance dose indicating even greater weight loss will be presented at the 2023 American Diabetes Association's 83rd Scientific Sessions in San Diego, California. Until then, the data is under embargo.

05:21 EDT Hecla Mining reports Q1 adjusted EPS 1c, consensus 2c - Reports Q1 revenue $199.5M, consensus $198.42M. The company produced 4M ounces of silver in Q1. "As we continue our growth in silver production, silver revenues are now exceeding gold revenues for the second consecutive quarter," said Phillips Baker Jr., president and CEO. "Greens Creek had excellent operational performance achieving record throughput and very strong silver and record gold production, and Lucky Friday exceeded 1.2 million ounces of silver production for third time out of the last four quarters."